Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
The assessment of cancer immunotherapy requires the use of appropriate preclinical animal models that sufficiently reflect the physiological situation in humans.
Oncodesign actively works for your cancer programs through the development of custom-made humanized mouse models: mice co-transplanted with both human tumor and human immune or hematopoietic progenitor cells.
Oncodesign’s scientific teams ran studies on tailored-made humanized immune system (HIS) models to evaluate immunomodulatory agents. Findings are showing therapeutic efficiency assessed by the monitoring of mice survival and tumor growth. The impact of therapeutics on tumors and immune cells was assessed by flow cytometry and immunohistochemistry analyses.
Key learning objectives
How to custom-made humanized immune system (HIS) models for cancer immunotherapy research
Case study & results: evaluation of immuno-onco biologics & demonstration of antitumor effect in HIS model
Parameters to consider for HIS model selection
Advantages/limitations of each HIS model
About our speaker Caroline Mignard
Caroline Mignard has obtained a Ph.D in Biology from the University of Strasbourg in France and has more than 15 years of experience in preclinical research. As study director at Oncodesign, Caroline has been working closely with our clients to select the most appropriate study designs for the evaluation of their therapies through preclinical studies.
Caroline is also involved in IMODI, (Innovative MODels Initiative) a French consortium dedicated to the development, the characterization and the commercialization of new preclinical models in oncology, including PDX models and humanized mouse models. She is the co-author of several publications about PDX models.
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260